Hematology Oncology Snippets

Share this post

User's avatar
Hematology Oncology Snippets
Dara-KRd + Tandem autoSCT for high-risk Transplant-Eligible Multiple Myeloma

Dara-KRd + Tandem autoSCT for high-risk Transplant-Eligible Multiple Myeloma

IFM 2018-04

Astha Thakkar's avatar
Astha Thakkar
Mar 05, 2024
∙ Paid
1

Share this post

User's avatar
Hematology Oncology Snippets
Dara-KRd + Tandem autoSCT for high-risk Transplant-Eligible Multiple Myeloma
Share

Background : Multiple myeloma is a cancer of plasma cells. About 15% of multiple myeloma harbors high-risk cytogenetic features. It is important to study the efficacy of treatment in this patient population as they are at high-risk of shorter remissions, disease relapses, refractory disease and ultimately death from multiple myeloma.

The IFM 2018-04 st…

Keep reading with a 7-day free trial

Subscribe to Hematology Oncology Snippets to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 Astha Thakkar
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share